Core Viewpoint - The company plans to adjust the investment construction progress of certain fundraising projects, specifically postponing the expected operational date of the "Composite External Insulation Product Expansion Project (Phase I)" from August 2025 to December 31, 2025, and will conclude the "Digital Factory Construction Project for Composite Crossarms" [1][2][13]. Fundraising Project Adjustments - The company will transfer the surplus fundraising amount of 11.894 million yuan (after deducting bank fees) to the "Composite External Insulation Product Expansion Project (Phase I)" [1][11]. - The total amount raised from the non-public offering in 2020 was approximately 424 million yuan, with a net amount of about 418 million yuan after deducting issuance costs [2][4]. Project Status and Financial Management - As of July 31, 2025, the "Composite External Insulation Product Expansion Project (Phase I)" has completed the process route verification and design, equipment selection, and partial equipment procurement and installation [8][9]. - The company has effectively managed idle fundraising by investing in financial products, generating additional income [11][12]. Board Decisions and Compliance - The adjustments were approved in the board meeting held on August 12, 2025, and do not require shareholder approval as they do not alter the project implementation entity, fundraising purposes, or investment scale [12][13]. - The sponsor, Huatai United Securities, has confirmed that the adjustments comply with relevant regulations and will not adversely affect the company's operations or shareholder interests [12][14].

华泰联合证券有限责任公司关于 江苏神马电力股份有限公司 调整部分募投项目投资建设进度暨部分募投项目结项并将 节余募集资金用于其他募投项目的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为江苏神马电力股份有限公司（以下简称"神马电力"或"公司"）2020 年非公 开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集 资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等相关法律法规和规范性文件的规定，对公司调整部分募投项目投资建设进度暨 部分募投项目结项并将节余募集资金用于其他募投项目进行了认真、审慎的核查， 并发表意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准江苏神马电力股份有限公司非公开发 行股票的批复》（证监许可[2021]346 号），公司非公开发行 32,218,837 股，每 股发行价格为人民币 13.16 元，共计募集资金人民币 423,999,894.92 元，扣除相 关发行费用 5,716,837.75 元（不含税）后，非公开发行实际募集资金净额为人民 币 418,283,057.17 元。 上述募 ...

证券代码：301168 证券简称：通灵股份 公告编号：2025-045 江苏通灵电器股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏通灵电器股份有限公司（以下简称"公司"或"本公司"）第五届董 事会第七次会议决定于2025年8月14日（星期四）召开公司2025年第二次临时股 东会，现将大会有关事项通知如下： 一、召开会议的基本情况 开。 （1）现场投票：股东本人出席本次会议现场会议或者通过授权委托书授权 他人出席现场会议； （2）网络投票：本次股东会通过深圳证券交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络形式的投票平台，股权登记日 登记在册的公司股东可以在网络投票时间内通过上述系统行使表决权。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体已发 行有表决权股份的股东均有权出席股东会，并可以以书面形式委托代 ...

河北广电无线传媒股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301551 证券简称：无线传媒 公告编号：2025-021 表决结果：3票同意，0票反对，0票弃权。 （二）审议通过《关于对外投资设立控股子公司暨关联交易的议案》 经审议，监事会认为：本次公司与关联方共同投资设立控股子公司暨关联交 易事项与公司目前经营需要和未来战略发展相符合。本次交易不会对公司的财务 状况、经营成果造成重大不利影响，不会影响公司独立性，不存在损害公司及全 体股东的利益，特别是中小股东的利益情形。因此，监事会一致同意公司与关联 方共同投资设立控股子公司暨关联交易事项。 详细内容请参见公司同日在《证券时报》《证券日报》《中国证券报》《上 海证券报》及巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于对外投资 设立控股子公司暨关联交易的公告》。 一、监事会会议召开情况 河北广电无线传媒股份有限公司（以下简称"公司"）第二届监事会第十一 次会议的通知于2025年8月1日以电子邮件等方式送达全体监事，并于2025年8月 监事3人，其中窦为 ...

Fundraising Overview - The actual net amount raised by the company through the issuance of A-shares is approximately RMB 1.84 billion [1] - As of October 13, 2023, the remaining funds after deducting underwriting and other issuance costs amount to approximately RMB 1.84 billion [2] Fund Management - The company has established a dedicated account storage system for the raised funds to ensure proper supervision and management [2] - The management procedures for the raised funds have been revised multiple times, with the latest revision occurring on May 8, 2023 [2] Fund Usage - As of June 30, 2025, the company has invested approximately RMB 404.22 million into fundraising projects [2] - The total amount of funds that have been used for investment projects in 2025 is approximately RMB 184.16 million [6] Project Adjustments - The company has approved changes to the implementation subjects of certain fundraising projects, including the addition of the company itself as a subject for the "Beidou + 5G" project [5] - Adjustments to the investment amounts and internal investment structure of fundraising projects have been approved, with a reduction of RMB 120 million for the "Beidou + 5G" project and an increase of the same amount for the "Tianshu R&D Center Construction" project [5][7] Cash Management - The company has approved the use of up to RMB 1.2 billion of temporarily idle raised funds for cash management, which can be used within 12 months from the date of approval [6] - As of June 30, 2025, the balance of temporarily idle funds used for cash management is approximately RMB 1.12 billion [6] Remaining Funds - As of June 30, 2025, the company has approximately RMB 1.29 billion of unutilized raised funds, which are stored in dedicated accounts and wealth management accounts [7]

Core Viewpoint - The company has decided to extend the timeline for the project "Design and Deployment of Smart Systems for Shared Assistive Vehicles" to December 2027, while maintaining the project's investment scope and structure unchanged [1][4]. Fundraising Overview - The company issued 8,864,800 convertible bonds with a face value of 100 RMB each, raising a total of 88,648 million RMB, with a net amount of 86,000.11 million RMB after deducting issuance costs [1][2]. Fund Usage Status - As of June 30, 2025, the total investment for the project is 88,648 million RMB, with 62,250.16 million RMB utilized, representing a usage progress of 70.22% [2]. Reasons for Timeline Adjustment - The adjustment is due to the impact of macroeconomic conditions and regional policies on the shared mobility sector, leading to a decrease in revenue and slower project implementation. The company aims to align project timelines with market demand and operational realities [2][3]. Measures for Project Continuation - The company plans to expand its shared assistive bicycle projects in various regions from 2025 to 2027, responding to increased demand and technological upgrades [2][3]. Compliance and Governance - The company will adhere to relevant regulations and ensure efficient resource allocation to support the project's timely and high-quality completion [3][5]. Impact on Operations - The adjustment of the project timeline is a cautious decision based on objective circumstances and will not significantly affect the company's operations or shareholder interests [4][5].

Fundraising Overview - The company raised a total of RMB 1,400,732,340.85 through its initial public offering, with the funds deposited in a designated account on December 16, 2021 [1] - As of June 30, 2025, the company has utilized RMB 573,704,200.00 of the raised funds, with RMB 46,799,400.00 used in the current year, all allocated to fundraising projects [1][2] - The remaining balance of the raised funds is RMB 935,461,000.00, which includes RMB 108,432,900.00 in net interest income after deducting fees [1] Fund Management - The company has established a fundraising management system to ensure compliance with regulatory requirements and protect investor interests, which was approved by the board on July 25, 2020 [1] - The company has signed a tripartite supervision agreement with its sponsor and a local bank to enhance the management and efficiency of the raised funds [1][2] Fund Usage and Adjustments - The company has reported that there are no fundraising projects that cannot be individually accounted for in terms of benefits [2] - The company has adjusted its fundraising usage plan, reallocating funds from the "annual production of 1,200 tons of raw materials project" to the "high-end pharmaceutical formulation internationalization project," with a total investment of RMB 33,227,000.00 planned for the latter [3][4] - The company has decided to terminate the "annual production of 5,000 tons of ibuprofen raw materials project" due to market saturation and price decline, reallocating the remaining funds to other projects [3][5] Project Progress and Timeline - The two fundraising projects, "annual production of 700 tons of raw materials project" and "annual production of 12 tons of anti-tumor raw materials project," are expected to reach usable status by December 2024, with ongoing construction and testing [3][5] - The "high-end pharmaceutical formulation internationalization project" is also facing delays, with an expected completion date extended to December 2026 due to regulatory and market factors [3][4]

Core Viewpoint - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss adjustments to fundraising project investments and the use of excess funds raised from its initial public offering [5][12]. Meeting Procedures - The company has established guidelines for the meeting to ensure the rights of shareholders are protected and to facilitate orderly proceedings [1][2]. - Shareholders must register and present identification documents before the meeting starts, and latecomers will not be allowed to vote [2][3]. - The meeting will follow a predetermined agenda, allowing shareholders to express their opinions and vote on various proposals [2][4]. Fundraising Overview - The company successfully raised a total of RMB 87,598.50 million from its initial public offering, with a net amount of RMB 78,781.67 million after deducting issuance costs [5][6]. - The funds have been deposited in a dedicated account, and a tripartite supervision agreement has been signed with the underwriter and the bank [6][7]. Project Investment Adjustments - The company plans to adjust the investment amounts and internal structure of certain fundraising projects, including the "Distributed Fiber Optic Sensing System Upgrade R&D and Production Project" and the "Asset Digital Operation and Maintenance Platform R&D Project" [8][10]. - The total investment for the "Distributed Fiber Optic Sensing System Upgrade R&D and Production Project" will increase from RMB 30,908.93 million to RMB 33,650.12 million [10]. - The "Asset Digital Operation and Maintenance Platform R&D Project" will see its investment rise from RMB 8,000.28 million to RMB 9,221.58 million [10]. Impact of Adjustments - The adjustments to the investment amounts and the use of excess funds are intended to enhance the efficiency of fund utilization and optimize resource allocation, aligning with the company's long-term strategic goals [10][11]. - The company asserts that these changes will not adversely affect its normal operations or harm the interests of shareholders [10][11].

长江证券承销保荐有限公司 关于西安西测测试技术股份有限公司 调整部分募投项目内部结构及实施地点的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为西安 西测测试技术股份有限公司（以下简称"西测测试"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资 《深圳证券交易所上市公司自律监管指引第 13 号—— 金管理和使用的监管要求》 保荐业务》等相关法律、法规和规范性文件的规定，对西测测试调整部分募投项 目内部结构及实施地点的事项进行了审慎核查，核查情况及意见如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"） 《关于同意西安西测 （证监许可【2022】748 号） 测试技术股份有限公司首次公开发行股票注册的批复》 为规范公司募集资金管理，保护投资者权益，公司及公司控股子公司与保荐 人、募集资金专户开户银行签署了《募集资金三方/四方监管协议》，开设了募集 资金专项 ...

Core Viewpoint - The report provides a comprehensive overview of the fundraising activities and the utilization of funds by Shanghai Aiwei Electronics Technology Co., Ltd. as of June 30, 2025, ensuring compliance with regulatory guidelines and reflecting the company's financial management practices [1][3]. Fundraising Overview - The total amount raised through the public offering was RMB 3,201,044,000, with a net amount of RMB 3,035,261,414 after deducting issuance costs [3]. - The funds were deposited into a designated bank account, with specific details on the account balances and management practices outlined [3]. Fund Utilization - As of June 30, 2025, the company had utilized RMB 2,165,506,800, accounting for 71.34% of the net fundraising amount, with a remaining balance of RMB 984,051,900 [12]. - The company adjusted the investment amount for the "R&D Center Construction Project" from RMB 408.25 million to RMB 218.92 million, reallocating the remaining funds to the "Electronic Engineering Testing Center Construction Project" [4]. Temporary Fund Management - The company approved the temporary use of idle funds, allowing up to RMB 780 million for operational needs, which was fully returned by August 22, 2022 [5]. - A subsequent approval allowed for the use of up to RMB 600 million in idle funds, which was also returned by August 15, 2024 [6][8]. Cash Management - The company engaged in cash management activities, utilizing idle funds for purchasing low-risk financial products, with a total of RMB 250 million allocated for such investments as of June 30, 2025 [12][10]. Project Adjustments and Economic Benefits - The company has made adjustments to project timelines, extending the expected completion date for the "Electronic Engineering Testing Center Construction Project" from August 2024 to March 2026 [4]. - Several projects, including the R&D Center and various chip development initiatives, are still under construction and do not yet generate direct economic benefits [18]. Compliance and Reporting - The report confirms that the actual use of funds aligns with previously disclosed information, ensuring transparency and adherence to regulatory requirements [19].